Peter M Glazer

List of Publications by Year
in descending order

191 papers	12,133 citations	20817 60 h-index	30922 102 g-index
195 all docs	195 docs citations	195 times ranked	13054 citing authors

#	Article	IF	Citations
1	Antispacer peptide nucleic acids for sequence-specific CRISPR-Cas9 modulation. Nucleic Acids Research, 2022, 50, e59-e59.	14.5	7
2	Clinical Efficacy of Olaparib in <i>IDH1/IDH2-</i>Mutant Mesenchymal Sarcomas. JCO Precision Oncology, 2021, 5, 466-472.	3.0	24
3	Cooperation between oncogenic Ras and wild-type p53 stimulates STAT non-cell autonomously to promote tumor radioresistance. Communications Biology, 2021, 4, 374.	4.4	11
4	Nanoparticles for delivery of agents to fetal lungs. Acta Biomaterialia, 2021, 123, 346-353.	8.3	15
5	Targeting the Hypoxic and Acidic Tumor Microenvironment with pH-Sensitive Peptides. Cells, 2021, 10, 541.	4.1	33
6	Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity. NAR Cancer, 2021, 3, zcab021.	3.1	16
7	The NIH Somatic Cell Genome Editing program. Nature, 2021, 592, 195-204.	27.8	84
8	Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without <i>BRCA</i> Mutation. Oncologist, 2021, 26, e1104-e1109.	3.7	9
9	Peptide nucleic acids and their role in gene regulation and editing. Biopolymers, 2021, 112, e23460.	2.4	17
10	BBIT20 inhibits homologous DNA repair with disruption of the BRCA1â€“BARD1 interaction in breast and ovarian cancer. British Journal of Pharmacology, 2021, 178, 3627-3647.	5.4	13
11	Abstract LB169: Systemic Administration of an antibody/RNA complex results in tumor specific delivery of immunostimulatory RNAs and tumor growth suppression in a mouse model of melanoma. , 2021, , .		1
12	Vulnerability of IDH1-Mutant Cancers to Histone Deacetylase Inhibition via Orthogonal Suppression of DNA Repair. Molecular Cancer Research, 2021, 19, 2057-2067.	3.4	10
13	Regulation of the Cell-Intrinsic DNA Damage Response by the Innate Immune Machinery. International Journal of Molecular Sciences, 2021, 22, 12761.	4.1	10
14	Impact of hypoxia on DNA repair and genome integrity. Mutagenesis, 2020, 35, 61-68.	2.6	47
15	Tumor-Targeted, Cytoplasmic Delivery of Large, Polar Molecules Using a pH-Low Insertion Peptide. Molecular Pharmaceutics, 2020, 17, 461-471.	4.6	15
16	Tumor-targeted pH-low insertion peptide delivery of theranostic gadolinium nanoparticles for image-guided nanoparticle-enhanced radiation therapy. Translational Oncology, 2020, 13, 100839.	3.7	13
17	Hypoxia Induces Resistance to EGFR Inhibitors in Lung Cancer Cells via Upregulation of FGFR1 and the MAPK Pathway. Cancer Research, 2020, 80, 4655-4667.	0.9	52
18	Oncometabolites suppress DNA repair by disrupting local chromatin signalling. Nature, 2020, 582, 586-591.	27.8	183

#	Article	IF	Citations
19	Ku80-Targeted pH-Sensitive Peptideâ€“PNA Conjugates Are Tumor Selective and Sensitize Cancer Cells to Ionizing Radiation. Molecular Cancer Research, 2020, 18, 873-882.	3.4	18
20	Pharmacological methods to transcriptionally modulate double-strand break DNA repair. International Review of Cell and Molecular Biology, 2020, 354, 187-213.	3.2	8
21	Peptide Nucleic Acids and Gene Editing: Perspectives on Structure and Repair. Molecules, 2020, 25, 735.	3.8	44
22	Poly(Lactic-co-Glycolic Acid) Nanoparticle Delivery of Peptide Nucleic Acids In Vivo. Methods in Molecular Biology, 2020, 2105, 261-281.	0.9	10
23	Abstract 6249: CBX-12: A low pH targeting alphalexâ„¢-exatecan conjugate for the treatment of solid tumors. Cancer Research, 2020, 80, 6249-6249.	0.9	2
24	Synthetic lethality of a cell-penetrating anti-RAD51 antibody in PTEN-deficient melanoma and glioma cells. Oncotarget, 2019, 10, 1272-1283.	1.8	21
25	Optimizing biodegradable nanoparticle size for tissue-specific delivery. Journal of Controlled Release, 2019, 314, 92-101.	9.9	43
26	Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51. Science Translational Medicine, 2019, 11, .	12.4	111
27	High-throughput Evaluation of Protein Migration and Localization after Laser Micro-Irradiation. Scientific Reports, 2019, 9, 3148.	3.3	6
28	Mitochondrial DNA stress signalling protects the nuclear genome. Nature Metabolism, 2019, 1, 1209-1218.	11.9	87
29	Abstract 2981: Targeting solid tumor acidic microenvironment with an alphalex PARP inhibitor. , 2019, , .		1
30	Suppressing miR-21 activity in tumor-associated macrophages promotes an antitumor immune response. Journal of Clinical Investigation, 2019, 129, 5518-5536.	8.2	92
31	Unlocking PARP inhibitor efficacy for HRD-negative cancers using the alphalex tumor targeting platform inhibitor efficacy for HRD-negative cancers using the alphalex tumor targeting platform.. Journal of Clinical Oncology, 2019, 37, e14664-e14664.	1.6	2
32	The hypoxic tumor microenvironment in vivo selects the cancer stem cell fate of breast cancer cells. Breast Cancer Research, 2018, 20, 16.	5.0	88
33	Electron-Mediated Aminyl and Iminyl Radicals from C5 Azido-Modified Pyrimidine Nucleosides Augment Radiation Damage to Cancer Cells. Organic Letters, 2018, 20, 7400-7404.	4.6	14
34	Pathologic Oxidation of PTPN12 Underlies ABL1 Phosphorylation in Hereditary Leiomyomatosis and Renal Cell Carcinoma. Cancer Research, 2018, 78, 6539-6548.	0.9	12
35	Mcp1 Promotes Macrophage-Dependent Cyst Expansion in Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2018, 29, 2471-2481.	6.1	78
36	Debugging the genetic code: Non-viral inÂvivo delivery of therapeutic genome editing technologies. Current Opinion in Biomedical Engineering, 2018, 7, 24-32.	3.4	12

#	Article	IF	Citations
37	PTEN Regulates Nonhomologous End Joining By Epigenetic Induction of NHEJ1/XLF. Molecular Cancer Research, 2018, 16, 1241-1254.	3.4	20
38	In utero nanoparticle delivery for site-specific genome editing. Nature Communications, 2018, 9, 2481.	12.8	124
39	Hypoxia Promotes Resistance to EGFR Inhibition in NSCLC Cells via the Histone Demethylases, LSD1 and PLU-1. Molecular Cancer Research, 2018, 16, 1458-1469.	3.4	60
40	Peptide Nucleic Acids as a Tool for Site-Specific Gene Editing. Molecules, 2018, 23, 632.	3.8	57
41	Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair. Nature Genetics, 2018, 50, 1086-1092.	21.4	152
42	Suppression of homology-dependent DNA double-strand break repair induces PARP inhibitor sensitivity in<i>VHL</i>-deficient human renal cell carcinoma. Oncotarget, 2018, 9, 4647-4660.	1.8	22
43	2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Science Translational Medicine, 2017, 9, .	12.4	420
44	Regulation of DNA Repair by Hypoxia. , 2017, , 169-188.		0
45	DNA Polymerase Beta Germline Variant Confers Cellular Response to Cisplatin Therapy. Molecular Cancer Research, 2017, 15, 269-280.	3.4	22
46	Nickel induces transcriptional down-regulation of DNA repair pathways in tumorigenic and non-tumorigenic lung cells. Carcinogenesis, 2017, 38, 627-637.	2.8	37
47	A cell-penetrating antibody inhibits human RAD51 via direct binding. Nucleic Acids Research, 2017, 45, 11782-11799.	14.5	19
48	Anti-tumor Activity of miniPEG-Î³-Modified PNAs to Inhibit MicroRNA-210 for Cancer Therapy. Molecular Therapy - Nucleic Acids, 2017, 9, 111-119.	5.1	61
49	Induction of a BRCAness state by oncometabolites and exploitation by PARP inhibitors.. Journal of Clinical Oncology, 2017, 35, 11586-11586.	1.6	0
50	Therapeutic Peptide Nucleic Acids: Principles, Limitations, and Opportunities. Yale Journal of Biology and Medicine, 2017, 90, 583-598.	0.2	65
51	Precise Genome Modification Using Triplex Forming Oligonucleotides and Peptide Nucleic Acids. Advances in Experimental Medicine and Biology, 2016, , 93-110.	1.6	1
52	In vivo correction of anaemia in Î²-thalassemic mice by Î³PNA-mediated gene editing with nanoparticle delivery. Nature Communications, 2016, 7, 13304.	12.8	143
53	Nanotechnology for delivery of peptide nucleic acids (PNAs). Journal of Controlled Release, 2016, 240, 302-311.	9.9	55
54	miR-155 Overexpression Promotes Genomic Instability by Reducing High-fidelity Polymerase Delta Expression and Activating Error-Prone DSB Repair. Molecular Cancer Research, 2016, 14, 363-373.	3.4	33

#	Article	IF	Citations
55	Genomic predictors of biochemical failure following radical prostatectomy.. Journal of Clinical Oncology, 2016, 34, 114-114.	1.6	0
56	DNA-dependent targeting of cell nuclei by a lupus autoantibody. Scientific Reports, 2015, 5, 12022.	3.3	41
57	Tumor suppressor p53 stole the AKT in hypoxia. Journal of Clinical Investigation, 2015, 125, 2264-2266.	8.2	6
58	YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors. Molecular Cancer Research, 2015, 13, 1389-1397.	3.4	18
59	Nanoparticles that deliver triplex-forming peptide nucleic acid molecules correct F508del CFTR in airway epithelium. Nature Communications, 2015, 6, 6952.	12.8	114
60	Mechanism of Action Studies of Lomaiviticin A and the Monomeric Lomaiviticin Aglycon. Selective and Potent Activity Toward DNA Double-Strand Break Repair-Deficient Cell Lines. Journal of the American Chemical Society, 2015, 137, 5741-5747.	13.7	17
61	LKB1 preserves genome integrity by stimulating BRCA1 expression. Nucleic Acids Research, 2015, 43, 259-271.	14.5	17
62	Multifaceted control of DNA repair pathways by the hypoxic tumor microenvironment. DNA Repair, 2015, 32, 180-189.	2.8	122
63	MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature, 2015, 518, 107-110.	27.8	709
64	Modified Poly(lacticâ€‹<i>co</i>â€‹glycolic Acid) Nanoparticles for Enhanced Cellular Uptake and Gene Editing in the Lung. Advanced Healthcare Materials, 2015, 4, 361-366.	7.6	37
65	Therapeutic Genome Mutagenesis Using Synthetic Donor DNA and Triplex-Forming Molecules. Methods in Molecular Biology, 2015, 1239, 39-73.	0.9	5
66	Targeted Genome Modification via Triple Helix Formation. Methods in Molecular Biology, 2014, 1176, 89-106.	0.9	20
67	Hypoxic Stress Facilitates Acute Activation and Chronic Downregulation of Fanconi Anemia Proteins. Molecular Cancer Research, 2014, 12, 1016-1028.	3.4	39
68	Triplex-Mediated Genome Targeting and Editing. Methods in Molecular Biology, 2014, 1114, 115-142.	0.9	4
69	The cytotoxicity of (â^')-lomaiviticin A arises from induction of double-strand breaks in DNA. Nature Chemistry, 2014, 6, 504-510.	13.6	73
70	Interplay between DNA repair and inflammation, and the link to cancer. Critical Reviews in Biochemistry and Molecular Biology, 2014, 49, 116-139.	5.2	128
71	Silencing of the DNA Mismatch Repair Gene MLH1 Induced by Hypoxic Stress in a Pathway Dependent on the Histone Demethylase LSD1. Cell Reports, 2014, 8, 501-513.	6.4	60
72	microRNAs in Cancer Cell Response to Ionizing Radiation. Antioxidants and Redox Signaling, 2014, 21, 293-312.	5.4	83

#	Article	IF	Citations
73	HDAC6 Deacetylates and Ubiquitinates MSH2 to Maintain Proper Levels of MutSÎ±. Molecular Cell, 2014, 55, 31-46.	9.7	112
74	Peptide Nucleic Acid-Mediated Recombination for Targeted Genomic Repair and Modification. Methods in Molecular Biology, 2014, 1050, 207-222.	0.9	3
75	Single-Stranded γPNAs for In Vivo Site-Specific Genome Editing via Watson-Crick Recognition. Current Gene Therapy, 2014, 14, 331-342.	2.0	41
76	Radiation sensitivity and sensitization in melanoma. Pigment Cell and Melanoma Research, 2013, 26, 928-930.	3.3	9
77	Triplex-forming Peptide Nucleic Acids Induce Heritable Elevations in Gamma-globin Expression in Hematopoietic Progenitor Cells. Molecular Therapy, 2013, 21, 580-587.	8.2	15
78	Nanoparticle for delivery of antisense Î³PNA oligomers targeting CCR5. Artificial DNA, PNA & XNA, 2013, 4, 49-57.	1.4	31
79	Site-specific Genome Editing in PBMCs With PLGA Nanoparticle-delivered PNAs Confers HIV-1 Resistance in Humanized Mice. Molecular Therapy - Nucleic Acids, 2013, 2, e135.	5.1	37
80	Genetic Instability Induced by Hypoxic Stress. , 2013, , 151-181.		3
81	Hypoxia and DNA repair. Yale Journal of Biology and Medicine, 2013, 86, 443-51.	0.2	19
82	Targeting Cancer with a Lupus Autoantibody. Science Translational Medicine, 2012, 4, 157ra142.	12.4	76
83	Targeted Gene Modification of Hematopoietic Progenitor Cells in Mice Following Systemic Administration of a PNA-peptide Conjugate. Molecular Therapy, 2012, 20, 109-118.	8.2	44
84	Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302. Molecular Cancer Therapeutics, 2012, 11, 740-751.	4.1	166
85	Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer. Breast Cancer Research and Treatment, 2012, 136, 67-75.	2.5	46
86	Preclinical evaluation of Laromustine for use in combination with radiation therapy in the treatment of solid tumors. International Journal of Radiation Biology, 2012, 88, 277-285.	1.8	13
87	New Translational Possibilities for Microenvironmental Modulation of Radiosensitivity. Radiation Research, 2011, 176, 412-414.	1.5	2
88	Radiation Resistance in Cancer Therapy: Meeting Summary and Research Opportunities Report of an NCI Workshop held September 1â€“3, 2010. Radiation Research, 2011, 176, e0016-e0021.	1.5	3
89	Nanoparticles Deliver Triplex-forming PNAs for Site-specific Genomic Recombination in CD34+ Human Hematopoietic Progenitors. Molecular Therapy, 2011, 19, 172-180.	8.2	86
90	Polymer delivery systems for site-specific genome editing. Journal of Controlled Release, 2011, 155, 312-316.	9.9	15

#	Article	IF	Citations
91	Targeted Disruption of the CCR5 Gene in Human Hematopoietic Stem Cells Stimulated by Peptide Nucleic Acids. Chemistry and Biology, 2011, 18, 1189-1198.	6.0	54
92	Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells. Cancer Biology and Therapy, 2011, 12, 908-914.	3.4	108
93	Functional and physical interaction between the mismatch repair and FA-BRCA pathways. Human Molecular Genetics, 2011, 20, 4395-4410.	2.9	46
94	Reduced Level of Ribonucleotide Reductase R2 Subunits Increases Dependence on Homologous Recombination Repair of Cisplatin-Induced DNA Damage. Molecular Pharmacology, 2011, 80, 1000-1012.	2.3	17
95	Hypoxia-Induced Epigenetic Regulation and Silencing of the <i>BRCA1</i> Promoter. Molecular and Cellular Biology, 2011, 31, 3339-3350.	2.3	118
96	Radiation Resistance in Cancer Therapy: Meeting Summary and Research Opportunities: Report of an NCI Workshop held September 1-3, 2010. Radiation Research, 2011, , .	1.5	0
97	Radiation Resistance in Cancer Therapy: meeting summary and research opportunities. Report of an NCI Workshop held September 1-3, 2010. Radiation Research, 2011, 176, e0016-21.	1.5	1
98	The Tumor Microenvironment and DNA Repair. Seminars in Radiation Oncology, 2010, 20, 282-287.	2.2	46
99	MicroRNA-210 Regulates Mitochondrial Free Radical Response to Hypoxia and Krebs Cycle in Cancer Cells by Targeting Iron Sulfur Cluster Protein ISCU. PLoS ONE, 2010, 5, e10345.	2.5	276
100	Potentiation of Temozolomide Cytotoxicity by Inhibition of DNA Polymerase Î² Is Accentuated by BRCA2 Mutation. Cancer Research, 2010, 70, 409-417.	0.9	34
101	Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2201-2206.	7.1	193
102	Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms. Breast Cancer Research, 2010, 12, 203.	5.0	37
103	â€œMicroâ€•management of DNA repair genes by hypoxia. Cell Cycle, 2009, 8, 4009-4010.	2.6	5
104	Emerging Roles of microRNAs in the Molecular Responses to Hypoxia. Current Pharmaceutical Design, 2009, 15, 3861-3866.	1.9	75
105	Src-Induced Cisplatin Resistance Mediated by Cell-to-Cell Communication. Cancer Research, 2009, 69, 3619-3624.	0.9	34
106	Targeted correction of a thalassemia-associated Â-globin mutation induced by pseudo-complementary peptide nucleic acids. Nucleic Acids Research, 2009, 37, 3635-3644.	14.5	50
107	MicroRNA Regulation of DNA Repair Gene Expression in Hypoxic Stress. Cancer Research, 2009, 69, 1221-1229.	0.9	402
108	Repair of DNA lesions associated with triplexâ€forming oligonucleotides. Molecular Carcinogenesis, 2009, 48, 389-399.	2.7	63

#	Article	IF	Citations
109	Editorial [Hot Topic: Hypoxia and Tumor Progression (Guest Editors: Ranjit S. Bindra and Peter M.) Tj ETQq1 1 0.784314 rgBT /Overlock Molecular Medicine, 2009, 9, 399-400.	1.3	1
110	Hypoxic Tumor Microenvironment and Cancer Cell Differentiation. Current Molecular Medicine, 2009, 9, 425-434.	1.3	153
111	MEN1 and FANCD2 mediate distinct mechanisms of DNA crosslink repair. DNA Repair, 2008, 7, 476-486.	2.8	8
112	Chronic Hypoxia Decreases Synthesis of Homologous Recombination Proteins to Offset Chemoresistance and Radioresistance. Cancer Research, 2008, 68, 605-614.	0.9	286
113	Genomic Instability in Cancer. Novartis Foundation Symposium, 2008, 240, 133-151.	1.1	18
114	Correction of a splice-site mutation in the beta-globin gene stimulated by triplex-forming peptide nucleic acids. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 13514-13519.	7.1	83
115	Triplex-Mediated Gene Modification. Methods in Molecular Biology, 2008, 435, 175-190.	0.9	23
116	Site-directed gene mutation at mixed sequence targets by psoralen-conjugated pseudo-complementary peptide nucleic acids. Nucleic Acids Research, 2007, 35, 7604-7613.	14.5	40
117	Co-repression of mismatch repair gene expression by hypoxia in cancer cells: Role of the Myc/Max network. Cancer Letters, 2007, 252, 93-103.	7.2	90
118	Repair and recombination induced by triple helix DNA. Frontiers in Bioscience - Landmark, 2007, 12, 4288.	3.0	56
119	Hypoxia-induced genetic instabilityâ€"a calculated mechanism underlying tumor progression. Journal of Molecular Medicine, 2007, 85, 139-148.	3.9	128
120	Regulation of DNA repair in hypoxic cancer cells. Cancer and Metastasis Reviews, 2007, 26, 249-260.	5.9	191
121	CHK2-Dependent Phosphorylation of BRCA1 in Hypoxia. Radiation Research, 2006, 166, 646-651.	1.5	27
122	Site-Specific Gene Modification by PNAs Conjugated to Psoralen. Biochemistry, 2006, 45, 314-323.	2.5	40
123	Targeted Cross-linking of the Human Î²-Globin Gene in Living Cells Mediated by a Triple Helix Forming Oligonucleotideâ€. Biochemistry, 2006, 45, 1970-1978.	2.5	36
124	Induction of aberrant crypt foci in DNA mismatch repair-deficient mice by the food-borne carcinogen 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP). Cancer Letters, 2006, 244, 79-85.	7.2	4
125	Overexpression of the DNA mismatch repair factor, PMS2, confers hypermutability and DNA damage tolerance. Cancer Letters, 2006, 244, 195-202.	7.2	37
126	Repair of DNA interstrand cross-links: Interactions between homology-dependent and homology-independent pathways. DNA Repair, 2006, 5, 566-574.	2.8	40

#	Article	IF	Citations
127	Development of a statewide hospital plan for radiologic emergencies. International Journal of Radiation Oncology Biology Physics, 2006, 65, 16.e1-16.e15.	0.8	15
128	Mlh1-dependent suppression of specific mutations induced in vivo by the food-borne carcinogen 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP). Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2006, 594, 101-112.	1.0	8
129	Basal repression of BRCA1 by multiple E2Fs and pocket proteins at adjacent E2F sites. Cancer Biology and Therapy, 2006, 5, 1400-1407.	3.4	32
130	Differing patterns of genetic instability in mice deficient in the mismatch repair genes Pms2, Mlh1, Msh2, Msh3 and Msh6. Carcinogenesis, 2006, 27, 2402-2408.	2.8	68
131	Triplex-Stimulated Intermolecular Recombination at a Single-Copy Genomic Target. Molecular Therapy, 2006, 14, 392-400.	8.2	37
132	Alterations in DNA Repair Gene Expression under Hypoxia: Elucidating the Mechanisms of Hypoxia-Induced Genetic Instability. Annals of the New York Academy of Sciences, 2005, 1059, 184-195.	3.8	69
133	Targeted Genome Modification via Triple Helix Formation. Annals of the New York Academy of Sciences, 2005, 1058, 151-161.	3.8	41
134	Gene Therapy for Autosomal Dominant Disorders of Keratin. Journal of Investigative Dermatology Symposium Proceedings, 2005, 10, 47-61.	0.8	34
135	Genetic instability and the tumor microenvironment: towards the concept of microenvironment-induced mutagenesis. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005, 569, 75-85.	1.0	146
136	Triplex-Forming Oligonucleotides as Potential Tools for Modulation of Gene Expression. Anti-Cancer Agents in Medicinal Chemistry, 2005, 5, 319-326.	7.0	54
137	Hypoxia-Induced Down-regulation of BRCA1 Expression by E2Fs. Cancer Research, 2005, 65, 11597-11604.	0.9	313
138	Triplex-induced recombination and repair in the pyrimidine motif. Nucleic Acids Research, 2005, 33, 3492-3502.	14.5	39
139	Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. Radiotherapy and Oncology, 2005, 76, 168-176.	0.6	172
140	Distance and Affinity Dependence of Triplex-Induced Recombinationâ€. Biochemistry, 2005, 44, 3856-3864.	2.5	31
141	Hypoxia-Induced Phosphorylation of Chk2 in an Ataxia Telangiectasia Mutatedâ€“Dependent Manner. Cancer Research, 2005, 65, 10734-10741.	0.9	85
142	Peptide nucleic acids as agents to modify target gene expression and function. International Journal of Peptide Research and Therapeutics, 2005, 10, 335-345.	1.9	0
143	Peptide conjugates for chromosomal gene targeting by triplex-forming oligonucleotides. Nucleic Acids Research, 2004, 32, 6595-6604.	14.5	42
144	Cell-interdependent cisplatin killing by Ku/DNA-dependent protein kinase signaling transduced through gap junctions. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 6134-6139.	7.1	80

#	Article	IF	Citations
145	Targeted Gene Modification Using Triplex-Forming Oligonucleotides. , 2004, 262, 173-194.		19
146	Setting Standards in Gene Repair. Oligonucleotides, 2004, 14, 79-79.	2.7	4
147	Down-Regulation of Rad51 and Decreased Homologous Recombination in Hypoxic Cancer Cells. Molecular and Cellular Biology, 2004, 24, 8504-8518.	2.3	341
148	Targeted Genome Modification Via Triple Helix Formation. , 2004, , 27-43.		0
149	Molecular markers in clinical radiation oncology. Oncogene, 2003, 22, 5915-5925.	5.9	48
150	Decreased Expression of the DNA Mismatch Repair Gene Mlh1 under Hypoxic Stress in Mammalian Cells. Molecular and Cellular Biology, 2003, 23, 3265-3273.	2.3	255
151	Peptide nucleic acids as agents to modify target gene expression and function. International Journal of Peptide Research and Therapeutics, 2003, 10, 335-345.	1.9	1
152	Transcription Dependence of Chromosomal Gene Targeting by Triplex-forming Oligonucleotides. Journal of Biological Chemistry, 2003, 278, 3357-3362.	3.4	30
153	The potential for gene repair via triple helix formation. Journal of Clinical Investigation, 2003, 112, 487-494.	8.2	135
154	Peptide nucleic acids as agents to modify target gene expression and function. International Journal of Peptide Research and Therapeutics, 2003, 10, 335-345.	0.1	0
155	Human XPA and RPA DNA repair proteins participate in specific recognition of triplex-induced helical distortions. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 5848-5853.	7.1	112
156	Triplex-forming oligonucleotides: principles and applications. Quarterly Reviews of Biophysics, 2002, 35, 89-107.	5.7	131
157	IGF1 Receptor Expression Protects against Microenvironmental Stress Found in the Solid Tumor. Radiation Research, 2002, 158, 174-180.	1.5	41
158	Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet, The, 2002, 359, 1471-1477.	13.7	290
159	Site-directed recombination via bifunctional PNA-DNA conjugates. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 16695-16700.	7.1	113
160	Gene targeting via triple-helix formation. Progress in Molecular Biology and Translational Science, 2001, 67, 163-192.	1.9	71
161	Triplex-induced Recombination in Human Cell-free Extracts. Journal of Biological Chemistry, 2001, 276, 18018-18023.	3.4	91
162	Chromosome Targeting at Short Polypurine Sites by Cationic Triplex-forming Oligonucleotides. Journal of Biological Chemistry, 2001, 276, 38536-38541.	3.4	75

#	ARTICLE	IF	CITATIONS
163	Directed Gene Modification via Triple Helix Formation. Current Molecular Medicine, 2001, 1, 391-399.	1.3	14
164	Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy. , 2000, 88, 1091-1098.		32
165	Prognostic significance of cyclin D1 protein levels in early-stage larynx cancer treated with primary radiation. , 2000, 90, 22-28.		30
166	Cyclin D1 expression and early breast cancer recurrence following lumpectomy and radiation. International Journal of Radiation Oncology Biology Physics, 2000, 47, 1169-1176.	0.8	32
167	Mutagenesis in PMS2- and MSH2-deficient mice indicates differential protection from transversions and frameshifts. Carcinogenesis, 2000, 21, 1291-1296.	2.8	39
168	Triple-Helix Formation Induces Recombination in Mammalian Cells via a Nucleotide Excision Repair-Dependent Pathway. Molecular and Cellular Biology, 2000, 20, 990-1000.	2.3	130
169	Activation of human Î³-globin gene expression via triplex-forming oligonucleotide (TFO)-directed mutations in the Î³-globin gene 5â€² flanking region. Gene, 2000, 242, 219-228.	2.2	29
170	Specific Mutations Induced by Triplex-Forming Oligonucleotides in Mice. Science, 2000, 290, 530-533.	12.6	252
171	Mutagenesis in PMS2- and MSH2-deficient mice indicates differential protection from transversions and frameshifts. Carcinogenesis, 2000, 21, 1291-1296.	2.8	2
172	<i>BRCA1/BRCA2</i> Germline Mutations in Locally Recurrent Breast Cancer Patients After Lumpectomy and Radiation Therapy: Implications for Breast-Conserving Management in Patients With <i>BRCA1</i>/<i>BRCA2</i> Mutations. Journal of Clinical Oncology, 1999, 17, 3017-3024.	1.6	119
173	Chromosomal mutations induced by triplex-forming oligonucleotides in mammalian cells. Nucleic Acids Research, 1999, 27, 1176-1181.	14.5	107
174	Targeted Correction of an Episomal Gene in Mammalian Cells by a Short DNA Fragment Tethered to a Triplex-forming Oligonucleotide. Journal of Biological Chemistry, 1999, 274, 11541-11548.	3.4	101
175	Triplex Formation by Oligonucleotides Containing 5-(1-Propynyl)-2â€˜-deoxyuridine:Â Decreased Magnesium Dependence and Improved Intracellular Gene Targetingâ€. Biochemistry, 1999, 38, 1893-1901.	2.5	54
176	Genome Modification by Triplex-Forming Oligonucleotides. Perspectives in Antisense Science, 1999, , 167-179.	0.2	1
177	Mutagenesis Mediated by Triple Helixâ€“Forming Oligonucleotides Conjugated to Psoralen: Effects of Linker Arm Length and Sequence Context. Photochemistry and Photobiology, 1998, 67, 289-294.	2.5	21
178	Targeted gene knockout mediated by triple helix forming oligonucleotides. Nature Genetics, 1998, 20, 212-214.	21.4	163
179	Mutagenesis induced by the tumor microenvironment. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1998, 400, 439-446.	1.0	102
180	Frequent spontaneous deletions at a shuttle vector locus in transgenic mice. Mutagenesis, 1996, 11, 49-56.	2.6	33

#	Article	IF	Citations
181	RecA protein-mediated irreversible fixation of an oligodeoxyribonucleotide to specific site in DNA. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1996, 351, 117-124.	1.0	3
182	Triplex-Mediated, in vitro Targeting of Psoralen Photoadducts within the Genome of a Transgenic Mouse. Photochemistry and Photobiology, 1996, 63, 207-212.	2.5	20
183	Other transgenic mutation assays: Tissue specificity of spontaneous point mutations in Î»supF transgenic mice. , 1996, 28, 459-464.		25
184	Targeted Mutagenesis Mediated by the Triple Helix Formation. , 1996, 57, 109-118.		4
185	Altered Repair of Targeted Psoralen Photoadducts in the Context of an Oligonucleotide-mediated Triple Helix. Journal of Biological Chemistry, 1995, 270, 22595-22601.	3.4	65
186	Induction of p53 in mouse cells decreases mutagenesis by UV radiation. Carcinogenesis, 1995, 16, 2295-2300.	2.8	35
187	Frequent T:Aâ†'G:C transversions in X-irradiated mouse cells. Carcinogenesis, 1995, 16, 83-88.	2.8	22
188	Site-specific targeting of psoralen photoadducts with a triple helix-forming oligonucleotide: characterization of psoralen monoadduct and crosslink formation. Nucleic Acids Research, 1994, 22, 2845-2852.	14.5	60
189	High efficiency, restriction-deficientin vitropackaging extracts for bacteriophage lambda DNA using a newE.colilysogen. Nucleic Acids Research, 1993, 21, 3903-3904.	14.5	50
190	Lambda phage shuttle vectors for analysis of mutations in mammalian cells in culture and in transgenic mice. Mutation Research - Reviews in Genetic Toxicology, 1989, 220, 263-268.	2.9	21
191	Oncogene Expression in Isogenic, EBV-Positive and -Negative Burkitt Lymphoma Cell Lines. Intervirology, 1985, 23, 82-89.	2.8	7